Oragenics, Inc.: Oragenics Initiates Phase IIa Clinical Trial Site Activation

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-tar ...

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIASARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a ...

Tampa Bay Functional Neurology Expands Access to Intensive Concussion Recovery Program on Florida’s Gulf Coast

Brandon-based functional neurology clinic introduces a structured fly-in rehabilitation program for post-concussion ...
Healio

Pilot lithium trial in mild cognitive impairment proves feasibility, informs further study

A pilot randomized trial of older adults with mild cognitive impairment given either daily low-dose lithium carbonate or placebo for 2 years met its feasibility target, according to results published ...
The Globe and Mail

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Sarasota, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”) a clinical-stage biotechnology company developing brain-targeted therapeutics through ...

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only ...
Clinical Advisor

Beyond the Hit: The Complex Pathophysiology and Management of Sport-Related Concussions

Sport-related concussions are mild traumatic brain injuries that demand timely recognition and management. This review explores current evidence on pathophysiology, diagnosis, and treatment strategies ...